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Abstract
Background: This study assessed the ability of mid-regional proadrenomedullin (MR-proADM) in comparison to
conventional biomarkers (procalcitonin (PCT), lactate, C-reactive protein) and clinical scores to identify disease
severity in patients with sepsis.
Methods: This is a secondary analysis of a randomised controlled trial in patients with severe sepsis or septic shock
across 33 German intensive care units. The association between biomarkers and clinical scores with mortality was
assessed by Cox regression analysis, area under the receiver operating characteristic and Kaplan-Meier curves.
Patients were stratified into three severity groups (low, intermediate, high) for all biomarkers and scores based on
cutoffs with either a 90% sensitivity or specificity.
Results: 1089 patients with a 28-day mortality rate of 26.9% were analysed. According to the Sepsis-3 definition, 41.
2% and 58.8% fulfilled the criteria for sepsis and septic shock, with respective mortality rates of 20.0% and 32.1%.
MR-proADM had the strongest association with mortality across all Sepsis-1 and Sepsis-3 subgroups and could
facilitate a more accurate classification of low (e.g. MR-proADM vs. SOFA: N = 265 vs. 232; 9.8% vs. 13.8% mortality)
and high (e.g. MR-proADM vs. SOFA: N = 161 vs. 155; 55.9% vs. 41.3% mortality) disease severity. Patients with
decreasing PCT concentrations of either ≥ 20% (baseline to day 1) or ≥ 50% (baseline to day 4) but continuously
high MR-proADM concentrations had a significantly increased mortality risk (HR (95% CI): 19.1 (8.0–45.9) and 43.1
(10.1–184.0)).
Conclusions: MR-proADM identifies disease severity and treatment response more accurately than established
biomarkers and scores, adding additional information to facilitate rapid clinical decision-making and improve
personalised sepsis treatment.
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Background
The incidence of sepsis has continued to escalate rapidly in
hospitalized patients [1], with mortality rates of between
10% and 54%, depending on disease severity [2, 3]. A
prompt assessment of the infectious load and disease sever-
ity in the early stages of sepsis is therefore crucial in order
to provide a rapid diagnostic and therapeutic response [4].
In addition, an accurate assessment of disease severity may
help to guide physicians in making efficient intensive care
unit (ICU) discharge decisions. However, to date, no diag-
nostic markers allow for a reliable severity assessment to be
made [4]. Clinical scores such as the Sequential Organ Fail-
ure Assessment (SOFA) score, Acute Physiological and
Chronic Health Evaluation (APACHE) II, and the Simpli-
fied Acute Physiological Score (SAPS) II have previously
been developed for this purpose [5]. However, such scores
may not promptly capture individual organ system dysfunc-
tion [4], and incorporation into daily routine is hampered
by their relative complexity. The use of biomarkers might
therefore satisfy this unmet clinical need.
Mid-regional proadrenomedullin (MR-proADM) is a
peptide generated by multiple tissues in order to stabilise
the microcirculation and protect against endothelial per-
meability [6–11], both of which are widely acknowledged
to play a significant role in the pathophysiological host
response to sepsis [12, 13]. Indeed, MR-proADM levels
are rapidly induced during the initial stages of sepsis de-
velopment following burns [14] and neurological disor-
ders [15], in response to invasive fungal infections in
patients with septic shock [16], and in other conditions
such as lower respiratory tract infections [17–19], lung
transplantation [20] and thoracic surgery [21]. Thus,
MR-proADM may be of significant clinical utility in the
early risk stratification of patients with sepsis. However,
supporting data from large patient populations are rare.
In this secondary analysis of a previous randomised
controlled trial [22], we aimed to investigate MR-
proADM performance in comparison to a range of bio-
markers (procalcitonin, lactate, C-reactive protein) and
clinical scores (SOFA, APACHE II and SAPS II) in order
to (i) make an accurate assessment of disease severity at
diagnosis and throughout ICU therapy, (ii) aid in the
early assessment of treatment response, and (iii) identify
low-risk patients eligible for an early ICU discharge to a
step-down unit.
Methods
Study design and patients
This is a secondary analysis of the randomised Placebo-
Controlled Trial of Sodium Selenite and Procalcitonin
Guided Antimicrobial Therapy in Severe Sepsis (SISPCT)
trial, performed across 33 German multidisciplinary
ICUs from November 2009 until February 2013 [22]. In-
clusion criteria were adults ≥ 18 years of age presenting
with new-onset severe sepsis or septic shock (≤ 24 h), ac-
cording to the Sepsis-1 definition [23]. The study proto-
col was approved by the ethics board of Jena University
Hospital. Written informed consent was obtained from
all patients or their legal representatives. For the purpose
of this analysis, patients were further classified according
to the Sepsis-3 definitions [4]. Details of the SISPCT
study design, data collection and management were de-
scribed previously [22].
Biomarker measurements
Patients were enrolled up to 24 h after diagnosis of severe
sepsis or septic shock, and serum C-reactive protein (CRP)
and lactate concentrations measured immediately there-
after. Additional blood samples were collected at baseline
and on days 1, 4, 7 and 10 and stored at the central study la-
boratory in Jena, Germany, at - 80 °C. MR-proADM and
procalcitonin (PCT) plasma concentrations were measured
retrospectively (Kryptor®, Thermo Fisher Scientific,
Germany) with a limit of detection of 0.05 nmol/L and 0.02
ng/ml, respectively. APACHE II and SAPS II scores were
calculated at baseline, whilst SOFA scores were calculated
at all time points.
Statistical analysis
The onset of either severe sepsis or septic shock was
considered as day 0 (baseline), irrespective of the prior
duration of hospital or ICU length of stay (LOS). Differ-
ences in demographic and clinical characteristics with
regards to 28-day mortality were assessed at baseline
using the chi-square (χ2) test for categorical variables,
and Student’s t test or the Mann-Whitney U test for
continuous variables, depending on distribution normal-
ity. Normally and non-normally distributed variables
were expressed as mean (standard deviation) and median
(first quartile to third quartile), respectively. The associ-
ation between mortality and each biomarker and clinical
score was assessed using area under the receiver operat-
ing characteristic curves (AUROC) and Cox regression
analysis, with multivariate analysis corrected for age, the
presence of comorbidities and septic shock. Net reclassi-
fication improvement (NRI) was used to evaluate the
additional performance of MR-proADM to individual
markers or scores across the total population and surviv-
ing and non-surviving patient groups [24]. For each bio-
marker and clinical score at each time point, two cutoffs
with a predefined sensitivity or specificity close to 90%
were derived from the AUROCs, allowing patients to be
classified into three severity subgroups (low, intermedi-
ate and high). A subgroup of clinically stable patients
was subsequently identified with an absence of any ICU-
associated procedures or complications, which included
focus eradication procedures, emergency surgery, new
infections, transfusion of blood products, infusion of
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colloids, invasive mechanical ventilation, renal/liver re-
placement or vasopressor therapy, and a deterioration in
the patient’s general clinical signs. Patients within this
group with low MR-proADM concentrations (which had
not increased since the previous measurement) were fur-
ther analysed. Mortality rates and average LOS were cal-
culated in both groups and compared to the patient
group discharged at each specific time point.
Finally, the response to ICU treatment was investigated
by constructing models of PCT, MR-proADM and SOFA
kinetics over time. Multivariate logistic regression was used
to assess the relationship of biomarkers and their interac-
tions at baseline, day 1 and day 4 with mortality, consider-
ing both absolute concentrations and the delta change
between time points. Accordingly, two models stratifying
patients based on PCT decreases of ≥20% or <20% from
baseline to day 1 and ≥50% or <50% from baseline to day 4
(based on a previous model [22]), and three models stratify-
ing patients with either decreasing (≥ 2 points), stable (< 2
point change) or increasing (≥ 2 points) SOFA scores from
baseline to day 1, were constructed. Patient subgroups were
subsequently identified according to MR-proADM concen-
trations, and respective mortality rates calculated. The risk
of mortality within each subgroup in comparison to other
subgroups was calculated by Cox regression analysis and il-
lustrated by Kaplan-Meier curves. The predicted risk of de-
veloping new infections and the requirement for focus
control procedures and emergency surgery over days 4 to 7
was subsequently investigated. All data were analysed using
the statistics software R (version 3.1.2).
Results
A total of 1089 patients with either severe sepsis (number
(N) = 142; 13.0%) or septic shock (N = 947; 87.0%) were
analysed. The 28-day all-cause mortality rate was 26.9%
with a hospital mortality rate of 33.4%. Of these patients,
439 (41.2%) and 627 (58.8%) fulfilled the criteria for sepsis
and septic shock according to the Sepsis-3 definition, with
28-day and hospital mortality rates of 20.0% and 24.4%
(sepsis) and 32.1% and 40.4% (septic shock), respectively.
Patient characteristics upon study enrollment for 28-day
mortality are summarized in Table 1. The most common
causes of mortality included sepsis-induced multiple organ
failure (N = 132; 45.7%), refractory septic shock (N = 54;
18.7%), death due to pre-existing illness (N = 35; 12.1%)
and acute respiratory insufficiency (N = 17; 5.9%). Other
causes not directly related to sepsis accounted for a mortal-
ity rate of 8.6%. A limitation of therapy was applied in 3.4%
of patients. Supplementary results on infectious foci and
microbial identification are reported in Additional file 1. In
general, non-surviving patients had significantly higher con-
centrations of MR-proADM, PCT and lactate, as well as
higher SOFA, APACHE II and SAPS II scores than survi-
vors. CRP concentrations were not significantly different.
Assocation between biomarkers and clinical scores with
mortality at baseline
AUROC, univariate and multivariate Cox regression ana-
lyses indicated that MR-proADM had the strongest asso-
ciation with 28-day mortality across the total patient
population, and within the Sepsis-1 (severe sepsis and
septic shock hazard ratio (HR) and interquartile range
(IQR) (95% confidence interval (CI)): 2.46 (1.45–4.15)
and 3.02 (2.48–3.69)) and Sepsis-3 (sepsis and septic
shock HR IQR (95% CI): 2.80 (2.04–3.84)) and 2.41
(1.97–2.96); Fig. 1) subgroups. Similar results were found
for 7-day, 90-day, ICU and hospital mortality prediction
in the total patient population (Table 2). The addition of
MR-proADM to all possible biomarker and clinical score
combinations (N = 63) significantly increased prognostic
performance according to likelihood ratio (LR) χ2 ana-
lysis within the bivariate and multivariate models (Add-
itional file 1: Table S1). There were also significant
increases in the AUROCs for individual biomarkers and
scores (Additional file 1: Table S2). Finally, net reclassifi-
cation improvement analysis resulted in a more accurate
classification following the addition of MR-proADM to
all biomarkers and scores (Additional file 1: Table S3),
and to an existing model of PCT and SOFA in the total
population (NRI (95% CI): 0.72 (0.58–0.83)), surviving
(NRI (95% CI): 0.32 (0.25–0.39)) and non-surviving (NRI
(95% CI)): 0.40 (0.29–0.47)) patient subgroups.
Identification of high-risk patients at baseline
All patients were further stratified into low, intermedi-
ate and high SOFA severity levels, and biomarker and
clinical score performance in predicting 28-day mor-
tality was assessed in each subgroup. MR-proADM
had the highest accuracy among all parameters in the
low (SOFA ≤7) and moderate (SOFA 8–13) severity
SOFA subgroups (Fig. 2; Additional file 1: Table S4).
Two corresponding MR-proADM cutoffs were subse-
quently calculated to identify low (≤ 2.75 nmol/L) and
high (> 10.9 nmol/L) severity patient populations at
baseline (Additional file 1: Table S5). Compared to
SOFA, a more accurate classification could be made
in identifying low (MR-proADM vs. SOFA, N = 265
vs. 232; 9.8% vs. 13.8% mortality) and high (MR-
proADM vs. SOFA, N = 161 vs. 155; 55.9% vs. 41.3%
mortality) disease severity patients (Additional file 1:
Table S6). A subgroup of 94 patients (9.3%) with high
MR-proADM concentrations and corresponding low/
intermediate SOFA values had respective 28 and 90-
day mortality rates of 57.4% and 68.9%, compared to
19.8% and 30.8% in the remaining low/intermediate
SOFA patient population. There were similar patterns
for MR-proADM performance in relation to SAPS II,
APACHE II and lactate, respectively ( Additional file 1:
Supplementary results and Tables S7–S9).
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Table 1 Clinical patient characteristics at baseline with regards to survival up to 28 days
Total
(N = 1076)
Survivors
(N = 787)
Non-Survivors
(N = 289)
p value
Age (years) (mean, SD) 65.7 (13.7) 64.3 (14.0) 69.5 (12.0) <0.001
Male gender (N, %) 681 (63.3%) 510 (64.8%) 171 (59.2%) 0.091
Definitions of sepsis and length of stay
Sepsis-1, severe sepsis (N, %) 139 (12.9%) 109 (13.9%) 30 (10.4%) 0.125
Sepsis-1, septic shock (N, %) 937 (87.1%) 678 (86.2%) 259 (89.6%) 0.125
Sepsis-3, sepsis (N, %) 439 (41.2%) 351 (45.2%) 88 (30.4%) <0.001
Sepsis-3, septic shock (N, %) 627 (58.8%) 426 (54.8%) 201 (69.6%) <0.001
ICU length of stay (days) (median, IQR) 12 (6 - 23) 13 (7 - 26) 8 (4 - 15) <0.001
Hospital length of stay (days) (median, IQR) 28 (17 - 45) 34 (22 - 51) 14 (7 - 23) <0.001
Pre-existing comorbidities
History of diabetes mellitus (N, %) 280 (26.0%) 188 (23.9%) 92 (31.8%) 0.009
Heart failure (N, %) 230 (21.4%) 150 (19.1%) 80 (27.7%) 0.003
Renal dysfunction (N, %) 217 (20.2%) 135 (17.2%) 82 (28.4%) <0.001
COPD (N, %) 131 (12.2%) 90 (11.4%) 41 (14.2%) 0.228
Liver cirrhosis (N, %) 50 (4.7%) 27 (3.4%) 23 (8.0%) 0.003
History of cancer (N, %) 319 (29.7%) 224 (28.5%) 95 (32.9%) 0.163
Immunosuppression (N, %) 46 (4.3%) 30 (3.8%) 16 (5.5%) 0.227
Microbiology
Gram positive (N, %) 146 (13.6%) 113 (14.4%) 33 (11.4%) 0.205
Gram negative (N, %) 132 (12.3%) 95 (12.1%) 37 (12.8%) 0.747
Fungal (N, %) 51 (4.7%) 37 (4.7%) 14 (4.8%) 0.922
Gram positive and negative (N, %) 183 (17.0%) 133 (16.9%) 50 (17.3%) 0.877
Gram positive and fungal (N, %) 92 (8.6%) 68 (8.6%) 24 (8.3%) 0.861
Gram negative and fungal (N, %) 51 (4.7%) 35 (4.5%) 16 (5.5%) 0.463
Gram positive and negative and fungal (N, %) 115 (10.7%) 81 (10.3%) 34 (11.8%) 0.492
Origin of infection
Pneumonia (N, %) 453 (43.7%) 327 (42.9%) 126 (46.0%) 0.380
Upper or lower respiratory (N, %) 44 (4.3%) 29 (3.8%) 15 (5.5%) 0.252
Thoracic (N, %) 44 (4.3%) 35 (4.6%) 9 (3.3%) 0.344
Bones/soft tissue (N, %) 78 (7.5%) 56 (7.4%) 22 (8.0%) 0.716
Gastrointestinal (N, %) 80 (7.7%) 68 (8.9%) 12 (4.4%) 0.011
Catheter associated (N, %) 30 (2.9%) 18 (2.4%) 12 (4.4%) 0.102
Surgical wound (N, %) 41 (4.0%) 31 (4.1%) 10 (3.7%) 0.759
Intraabdominal (N, %) 375 (36.2%) 276 (36.2%) 99 (36.1%) 0.979
Cardiovascular (N, %) 6 (0.6%) 4 (0.5%) 2 (0.7%) 0.708
Urogenital (N, %) 99 (9.6%) 70 (9.2%) 29 (10.6%) 0.503
Central nervous system (N, %) 3 (0.3%) 2 (0.3%) 1 (0.4%) 0.792
Bacteraemia (N, %) 31 (3.0%) 20 (2.6%) 11 (4.0%) 0.261
Organ dysfunction
Neurological (N, %) 348 (32.3%) 240 (30.5%) 108 (37.4%) 0.034
Respiratory (N, %) 486 (45.2%) 350 (44.5%) 136 (47.1%) 0.450
Cardiovascular (N, %) 829 (77.0%) 584 (74.2%) 245 (84.8%) <0.001
Renal (N, %) 382 (35.5%) 249 (31.6%) 133 (46.0%) <0.001
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Identification of low-risk patients throughout ICU stay
MR-proADM had the strongest association with 28-day
mortality across all subsequent time points (Add-
itional file 1: Table S10). Across days 4–10, a cutoff of
≤ 2.25 nmol/L identified more patients with a lower
mortality rate than the other biomarkers and clinical
scores (Additional file 1: Tables S11–S12). Accordingly,
290 low MR-proADM severity patients were identified on
day 4, of which 79 (27.2%) were deemed as clinically stable
with no increase in MR-proADM concentration from the
previous measurement (Table 3). A continuously low MR-
proADM concentration from day 1 was identified in 51
(64.6%) patients, whilst a decrease from an intermediate
to low severity level was observed in 28 (35.4%) patients.
Conversely, patients who maintained MR-proADM con-
centrations > 2.25 nmol/L at all time points had a signifi-
cantly higher 28-day mortality risk (Additional file 1:
Table S13). The average ICU LOS was 8 (7–10) days,
with a 28 and 90-day mortality rate of 0.0% and 1.4%,
respectively. In comparison, only 43 patients were ac-
tually discharged from the ICU on day 4, with a 28
and 90-day mortality rate of 2.3% and 10.0%, respect-
ively. MR-proADM concentration analysis within this
patient group indicated that 52.6%, 42.1% and 5.3% of
patients were discharged with low, intermediate and
high-severity concentrations, respectively. The results
were similar on ICU days 7 and 10.
Additional value of MR-proADM in the early identification
of treatment response
Multivariate logistic regression for all mortality periods ana-
lysed indicated that MR-proADM performance at baseline
and day 1 was independent of absolute PCT concentrations
or change in PCT between each time point. Results were
similar on day 4, with MR-proADM performance independ-
ent of delta PCT change. Absolute MR-proADM values had
the strongest predictive value for mortality, with delta change
in MR-proADM having no significant effect on mortality.
Accordingly, patients with decreasing PCT concen-
trations of ≥ 20% from baseline to day 1 (Fig. 3 and
Additional file 1: Table S14) or ≥ 50% from baseline to day
4 (Additional file 1: Figure S1 and Table S15) had a 28-day
mortality rate of 18.3% (N = 458) and 17.1% (N = 557), re-
spectively. This decreased to 5.6% (N = 125) and 1.8% (N
= 111) when patients had continuously low levels of MR-
proADM, and increased to 66.7% (N = 27) and 53.8% (N
= 39) in the presence of continuously high concentrations
(HR (95% CI): 19.1 (8.0–45.9) and 43.1 (10.1–184.0)). A
similar model of PCT and SOFA kinetics identified fewer
low severity patents who had a higher 28-day mortality
rate between baseline and day 1 (N = 102; 10.8% mortal-
ity) or day 4 (N = 64; 4.7% mortality), and identified fewer
high severity patients with lower mortality rates between
baseline and day 1 (N = 16; 50.0% mortality) or day 4 (N =
31; 41.9% mortality).
Table 1 Clinical patient characteristics at baseline with regards to survival up to 28 days (Continued)
Total
(N = 1076)
Survivors
(N = 787)
Non-Survivors
(N = 289)
p value
Haematological (N, %) 156 (14.5%) 89 (11.3%) 67 (23.2%) <0.001
Gastrointestinal (N, %) 387 (36.0%) 271 (34.4%) 116 (40.1%) 0.086
Metabolic (N, %) 718 (66.7%) 504 (64.0%) 214 (74.1%) 0.002
Other organ dysfunction (N, %) 499 (46.4%) 380 (48.3%) 119 (41.2%) 0.038
Treatment upon sepsis diagnosis
Invasive mechanical ventilation (N, %) 789 (73.3%) 567 (72.1%) 222 (76.8%) 0.113
Non-invasive mechanical ventilation (N, %) 64 (5.9%) 46 (5.8%) 18 (6.2%) 0.815
Renal replacement therapy (N, %) 326 (30.8%) 158 (20.5%) 168 (58.1%) <0.001
Vasopressor use (N, %) 980 (91.1%) 712 (90.5%) 268 (92.7%) 0.239
Biomarker and severity scores
MR-proADM (nmol/L) (median, IQR) 5.0 (2.6–8.8) 4.0 (2.3–7.2) 8.2 (5.2–12.6) <0.001
PCT (ng/mL) (median, IQR) 7.4 (1.6–26.9) 6.6 (1.4–25.1) 9.3 (2.6–31.8) 0.033
Lactate (mmol/L) (median, IQR) 2.7 (1.6–4.7) 2.4 (1.5–4.0) 3.7 (2.1–7.2) <0.001
CRP (mg/L) (median, IQR) 188 (120.9–282) 189 (120.5–277.4) 188 (122–287) 0.773
SOFA (points) (mean, SD) 10.02 (3.33) 9.58 (3.18) 11.22 (3.43) <0.001
SAPS II (points) (mean, SD) 63.27 (14.18) 61.08 (13.71) 69.24 (13.74) <0.001
APACHE II (points) (mean, SD) 24.24 (7.60) 23.05 (7.37) 27.49 (7.28) <0.001
Data are presented as absolute numbers with percentages in brackets, indicating the proportion of surviving and non-surviving patients at 28 days
APACHE II Acute Physiological and Chronic Health Evaluation II score, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, ICU intensive care unit,
MR-proADM mid-regional proadrenomedullin, N number, PCT procalcitonin, SAPS II Simplified Acute Physiological Score II, SOFA Sequential Organ Failure
Assessment score
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Furthermore, patients with decreasing PCT values of ≥
50% (baseline to day 4) had a significantly higher risk of de-
veloping subsequent nosocomial infections if corresponding
MR-proADM concentrations were either continuously high
(HR (95% CI): 3.9 (1.5–10.5)) or intermediate (HR (95%
CI): 2.4 (1.2–6.8)). In addition, patients with decreasing
PCT values of ≥ 50% but increasing intermediate to high
MR-proADM concentrations were subsequently more
likely to require focus control procedures compared to
those with either continuously intermediate (HR (95% CI):
3.2 (1.3–7.6)), intermediate to low (HR (95% CI): 8.7 (3.1–
24.8)) or high to intermediate (HR (95% CI): 4.6 (1.4–14.5))
values. When PCT levels failed to decrease by ≥ 50% over
the first 4 days of ICU treatment, the risk of requiring
emergency surgery was significantly increased if MR-
proADM concentrations were either at a continuously high
(HR (95% CI): 5.7 (1.5–21.9)) or intermediate (HR (95%
CI): 4.2 (1.3–13.2)) level.
Finally, despite undergoing ICU treatment, a stable
intermediate SOFA severity level persisted in 260 (26.6%)
patients from baseline to day 1, resulting in a 28-day mor-
tality rate of 26.2%. Of these patients, those with continu-
ously low or decreasing MR-proADM concentrations (N
= 80; 13.8% mortality) had a significantly lower mortality
rate compared to those with continuously high or increas-
ing concentrations (N = 40; 47.5% mortality; HR (95% CI):
0.1 (0.0–0.4)). Similar MR-proADM subgroups were also
identified within the populations with stable low, increas-
ing and decreasing SOFA.
Discussion
Sepsis remains a major public health concern with
high rates of morbidity, mortality and resource use
worldwide [25]. Although considerable advances have
been made to better define the host response to in-
fection, there is still a lack of specific tools to identify
a b c
Fig. 1 Prediction of 28-day mortality at baseline. Association between biomarkers and clinical scores with mortality at baseline, with respective AUROC
and Cox regression analyses across the total patient population (a), Sepsis-3 (b) and Septic shock-3 (c) subgroups. All multivariate analyses for 28-day mortality
were significant (p <0.001). APACHE II Acute Physiological and Chronic Health Evaluation II score, AUROC area under the receiver operating characteristic
curve, CI confidence interval, CRP C-reactive protein, HR hazard ratio, IQR interquartile range, MR-proADM mid-regional proadrenomedullin, N number,
PCT procalcitonin, SAPS II, Simplified Acute Physiological Score II, SOFA Sequential Organ Failure Assessment
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patients at risk of a poor outcome. Accordingly, nu-
merous biomarkers and clinical severity scores have
been proposed to fulfil such a requirement, with the
SOFA score (representing sepsis-related organ dys-
function) and serum lactate (indicating a deterioration
in tissue perfusion) both playing a central role in the
recent definition of sepsis [4]. Nevertheless, earlier in-
dicators of developing organ dysfunction or a deteri-
orating host response are essential in order to guide
the most appropriate therapeutic intervention at the
earliest opportunity [26, 27].
The novel biomarker, MR-proADM, may fulfil this
clinical unmet need, with previous experimental studies
showing adrenomedullin to play a significant role in vas-
cular permeability [6], inflammatory mediator and endo-
thelial barrier regulation, and stabilisation of the
microcirculation [9, 28, 29] - all of which contribute to
the development of organ dysfunction and failure. Ac-
cordingly, this secondary analysis of the SISPCT trial [22],
for the first time, compared sequential measurements of
conventional biomarkers and clinical scores, such as lac-
tate, PCT and SOFA, with those of MR-proADM.
Our results indicate that the initial use of MR-
proADM within the first 24 h after sepsis diagnosis
resulted in the strongest association with short-term,
mid-term and long-term mortality compared to all
Table 2 Survival analysis for 7-day, 90-day, ICU and hospital mortality
Univariate Cox regression Multivariate Cox regression
Biomarker or clinical score Patients
(N)
Mortality
(N)
AUROC LR χ2 C-index HR IQR
(95% CI)
p value LR χ2 C-index HR IQR
(95% CI)
7-day mortality MR-proADM 1037 131 0.72 71.6 0.71 3.3 (2.4–4.3) <0.001 82.1 0.73 3.4 (2.5–4.6)
PCT 1038 131 0.58 9.7 0.58 1.5 (1.2–2.0) 0.002 28.4 0.64 1.6 (1.2–2.1)
CRP 943 111 0.55 1.2 0.55 1.1 (0.9–1.4) 0.284 16.6 0.62 1.2 (0.9–1.4)
Lactate 1074 135 0.72 86.0 0.71 3.1 (2.4–3.9) <0.001 99.1 0.73 3.1 (2.4–4.0)
SOFA 1059 130 0.63 25.5 0.63 1.7 (1.4–2.0) <0.001 41.0 0.67 1.7 (1.4–2.1)
SAPS II 1085 135 0.66 38.5 0.66 1.8 (1.5–2.2) <0.001 50.1 0.67 1.8 (1.5–2.2)
APACHE II 1085 135 0.63 24.4 0.63 1.7 (1.4–2.1) <0.001 37.8 0.65 1.7 (1.4–2.1)
90-day mortality MR-proADM 1000 379 0.71 146.2 0.68 2.7 (2.3–3.2) <0.001 194.1 0.71 2.4 (2.0–2.8)
PCT 1000 379 0.55 11.8 0.55 1.3 (1.1–1.5) 0.001 113.5 0.65 1.3 (1.1–1.5)
CRP 909 348 0.51 0.2 0.51 1.0 (0.9–1.2) 0.664 92.3 0.64 1.1 (0.9–1.2)
Lactate 1037 399 0.64 83.2 0.63 2.0 (1.7–2.3) <0.001 168.8 0.68 1.9 (1.6–2.2)
SOFA 1021 388 0.62 48.1 0.61 1.5 (1.4–1.7) <0.001 143.7 0.67 1.5 (1.3–1.7)
SAPS II 1045 399 0.66 81.1 0.64 1.7 (1.5–1.9) <0.001 144.4 0.67 1.5 (1.3–1.7)
APACHE II 1045 399 0.67 86.4 0.64 1.8 (1.6–2.1) <0.001 146.8 0.67 1.6 (1.4–1.8)
ICU mortality MR-proADM 1023 264 0.73 136.4 0.73 4.0 (3.1–5.2) <0.001 158.3 0.75 3.7 (2.8–4.9)
PCT 1024 264 0.58 18.0 0.58 1.6 (1.3–2.0) <0.001 73.0 0.67 1.6 (1.3–2.1)
CRP 928 237 0.54 2.5 0.54 1.1 (1.0–1.3) 0.111 51.4 0.65 1.2 (1.0–1.4)
Lactate 1059 277 0.66 75.2 0.66 2.4 (2.0–3.0) <0.001 115.5 0.71 2.4 (1.9–2.9)
SOFA 1044 270 0.64 48.6 0.64 1.8 (1.5–2.2) <0.001 95.2 0.69 1.8 (1.5–2.2)
SAPS II 1070 277 0.65 58.7 0.65 1.9 (1.6–2.3) <0.001 91.2 0.68 1.8 (1.5–2.2)
APACHE II 1070 277 0.66 62.5 0.66 2.1 (1.7–2.6) <0.001 91.6 0.69 1.9 (1.5–2.3)
Hospital mortality MR-proADM 980 323 0.73 152.0 0.74 4.0 (3.1–5.2) <0.001 186.8 0.76 3.6 (2.7–4.6)
PCT 981 323 0.57 15.0 0.57 1.5 (1.2–1.9) <0.001 96.2 0.68 1.5 (1.2–1.9)
CRP 891 299 0.52 0.9 0.52 1.1 (0.9–1.3) 0.348 76.0 0.67 1.1 (1.0–1.3)
Lactate 1016 342 0.66 77.8 0.66 2.4 (2.0–2.9) <0.001 146.2 0.72 2.3 (1.9–2.9)
SOFA 1001 333 0.63 41.3 0.63 1.7 (1.4–2.0) <0.001 118.9 0.70 1.7 (1.4–2.0)
SAPS II 1027 342 0.65 59.1 0.65 1.9 (1.6–2.2) <0.001 115.9 0.69 1.7 (1.4–2.0)
APACHE II 1027 342 0.67 76.7 0.67 2.2 (1.9–2.7) <0.001 127.1 0.71 1.9 (1.6–2.4)
All multivariate p values <0.001, apart from PCT and CRP for 7-day mortality (0.002 and 0.084, respectively)
APACHE II Acute Physiological and Chronic Health Evaluation II score, CI confidence interval, CRP C-reactive protein, HR hazard ratio, IQR interquartile range, MR-
proADM mid-regional proadrenomedullin, N number, PCT procalcitonin, SAPS I I Simplified Acute Physiological Score II, SOFA Sequential Organ Failure Assessment
score, LR likelihood ratio
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a b c
Fig. 2 Cox regression and AUROC analysis for 28-day mortality prediction based on SOFA severity levels. Biomarker and clinical score performance in
predicting 28-day mortality with respective AUROC and Cox regression analyses in the low (SOFA ≤7) (a), moderate (SOFA 8–13) (b) and high (SOFA ≥14)
(c) severity SOFA subgroups. APACHE II Acute Physiological and Chronic Health Evaluation II score, AUROC area under the receiver operating characteristic
curve, CI confidence interval, CRP C-reactive protein, HR hazard ratio, IQR interquartile range, MR-proADM mid-regional proadrenomedullin, N number, PCT
procalcitonin, SAPS II Simplified Acute Physiological Score II, SOFA Sequential Organ Failure Assessment
Table 3 Mortality and duration of ICU therapy at different time points
Patient severity group Patients (N) SOFA (points) Length of stay
(days)
28-day mortality
(N, %)
90-day mortality
(N, %)
Day 4 Total patient population 777 8.4 (4.3) 16 (10–27) 158 (20.3%) 256 (33.9%)
Clinically stable population 145 4.5 (2.4) 8 (6–11) 10 (6.9%) 22 (15.8%)
Clinically stable and low MR-proADM population 79 3.6 (1.5) 8 (7–10) 0 (0.0%) 1 (1.4%)
Actual day-4 discharges 43 3.6 (2.1) – 1 (2.3%) 4 (10.0%)
Day 7 Total patient population 630 8.0 (4.2) 19 (13–31) 127 (20.2%) 214 (34.9%)
Clinically stable population 124 3.9 (1.7) 11.5 (9–16) 9 (7.3%) 17 (13.9%)
Clinically stable and low MR-proADM population 78 3.4 (1.6) 11 (9–14) 1 (1.3%) 4 (5.3%)
Actual day-7 discharges 36 3.6 (2.6) – 2 (5.6%) 5 (13.9%)
Day 10 Total patient population 503 7.6 (4.0) 23.5 (17–34.25) 82 (16.3%) 159 (32.6%)
Clinically stable population 85 3.5 (1.8) 15 (13–22) 9 (10.6%) 14 (17.3%)
Clinically stable and low MR-proADM population 57 3.2 (1.3) 14 (12.25–19) 1 (1.8%) 2 (3.8%)
Actual day-10 discharges 29 4.0 (2.6) – 5 (17.2%) 7 (24.1%)
N number, MR-proADM mid-regional proadrenomedullin, SOFA Sequential Organ Failure Assessment score
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other biomarkers or clinical scores. Previous studies
confirm our findings [30–32], whereas conflicting re-
sults [33] may be explained in part by the smaller
sample sizes analysed and by other factors highlighted
within this study, such as microbial species, origin of
infection and previous surgical history, all of which
may influence biomarker performance, thus adding to
the potential variability of results. Furthermore, our
study confirms the results of a previous investigation
highlighting the superior performance of MR-
proADM in low and intermediate severity organ dys-
function patients with severe sepsis or septic shock
[34]. Indeed, Andaluz-Ojeda et al. placed significant
importance on patients with low levels of organ dys-
function, since “this group represents either the
earliest presentation in the clinical course of sepsis
and/or the less severe form of the disease” [34]. The
incorporation of MR-proADM into an early sepsis
management protocol may therefore help guide early
diagnostic interventions and facilitate more intensive
treatment in these patient groups before development
of any further organ dysfunction. In addition, a rea-
sonable performance across all organ dysfunction,
Sepsis-1 and Sepsis-3 subgroups with respect to dis-
ease severity further strengthens its clinical utility ir-
respective of changing definitions or population
heterogeneity.
Further analysis of biomarker measurements through-
out ICU stay allowed for the effects of therapy to be
visualised, resulting in the discrimination of specific
a b
Fig. 3 Mortality rates at 28 and 90 days following PCT and MR-proADM kinetics between baseline and day 1. Kaplan-Meier plots illustrate patient subgroups
stratified by MR-proADM severity levels for 90-day mortality, based on corresponding PCT concentrations from baseline to day 1, decreasing either by ≥
20% (a) or by < 20% (b). Severity levels are grouped as continuously low, intermediate or high, or as a composite for increasing or decreasing MR-proADM
levels. Individual hazard ratios for comparisons between patient subgroups are indicated: *continuously intermediate vs. low values; **continuously high vs.
intermediate values; ***continuously high vs. low values; †increasing low to intermediate vs. continuously low values; ††increasing intermediate to high vs.
continuously intermediate values; ‡decreasing high to intermediate vs. continuously high values; ‡‡decreasing intermediate to low vs. continuously
intermediate values. HR hazard ratio, IQR interquartile range, MR-proADM mid-regional proadrenomedullin, N number, PCT procalcitonin
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patient groups according to host response. Based on the
results of this study, two further clinically important
uses for MR-proADM can be proposed: (i) the early es-
calation of therapy in patients at risk of treatment failure
and (ii) the de-escalation of treatment and early dis-
charge of low-risk patients.
First, our results revealed a significant benefit in the
addition of MR-proADM measurements in the early iden-
tification of non-responding patients in order to initiate
alternative targeted treatment strategies. Whilst decreas-
ing PCT concentrations are known to indicate the initi-
ation of successful antimicrobial therapy [35, 36], and
adherence to a PCT-guided algorithm has been shown to
facilitate a reduction in antibiotic use [22, 37, 38], our re-
sults revealed a significant benefit in the addition of MR-
proADM measurements. The presence of continuously
elevated or increasing MR-proADM concentrations in re-
lation to the high sensitivity cutoffs (2.75 and 10.9 nmol/
L) identified within this study - despite decreasing PCT
concentrations - may provide a prompt indication as to a
likely subsequent failure in treatment, and a poor overall
outcome. Similar results have been previously found in
critically ill febrile patients with cancer, where MR-
proADM concentrations were uniquely increased in pa-
tients who did not respond to therapy or antibiotic treat-
ment [39]. Such a biomarker constellation may therefore
be useful at an early stage of ICU therapy in order to fa-
cilitate the earlier initiation of specific interventions, such
as focus control and surgical procedures [16], or may po-
tentially aid in the streamlining of antimicrobial agents in
patients with sepsis or septic shock [40].
Second, the identification of a population with low dis-
ease severity who may be eligible for an early discharge to a
step-down setting may be of additional clinical and eco-
nomic interest [41]. A prompt discharge of patients no lon-
ger at risk is essential in maintaining an efficient bed-
management workflow as well as well as being of a likely
clinical benefit [42]. Our results suggest that the identifica-
tion of low levels of microcirculatory or vascular damage, as
indicated by low MR-proADM concentrations, identifies pa-
tients with a very low risk of death in whom early ICU dis-
charge might be possible, and may potentially prevent
unnecessary additional diagnostic or interventional proce-
dures [39, 43, 44]. Indeed, similarities have been shown in an
earlier randomised controlled trial of 313 patients with sus-
pected lower respiratory tract infections [19]. A non-
significant decrease in hospitalization of 0.5 days was identi-
fied at the 30-day follow up, although overruling of the MR-
proADM algorithm in 34.5% of cases after medical stabilisa-
tion resulted in delayed discharge, primarily due to organisa-
tional criteria such as further consultant examinations,
imaging studies or laboratory results. Such factors should
therefore be considered when designing further interven-
tional studies to confirm the results of this analysis.
Interestingly, the discharge of patients with varying MR-
proADM concentrations within our study potentially indi-
cated either an incomplete or insufficient treatment, which
was consequently reflected in an increased 28 and 90-day
mortality rate. Whilst it is unknown whether further ICU
treatment for non-microcirculatory, non-life-threatening is-
sues was required, or if beds in a step down-unit were avail-
able, such a biomarker-driven approach to ICU discharge in
addition to clinician judgement may reduce ICU LOS and
improve patient disposition stratification, with accompanied
clinical benefits and potential cost savings.
Our analysis has strengths and weaknesses. Biomarker
measurements were not collected on a daily basis and
were not available earlier than day 1. Given the secondary
analysis design of the study, our results should be viewed
as exploratory and hypothesis-generating. Admittedly,
some of the subgroups analyses involved small patient
numbers, revealing the need for future studies to confirm
the hypotheses generated. Strengths include the thorough
examination of several different subgroups with varying
disease severity from a randomised trial database with a
high internal validity, and the largest sample size of sepsis
patients with MR-proADM measurements to date.
Conclusions
MR-proADM provides a more accurate disease severity
and mortality risk stratification compared to clinically
established biomarkers and scores, both on initial diagnosis
and over the course of treatment. Changes in MR-proADM
kinetics, despite ongoing antimicrobial treatment, may be
used to identify patients at risk of treatment failure who
may require alternative diagnostic and therapeutic interven-
tions, as well as low severity patients eligible for an early
ICU discharge in conjunction with an absence of ICU-
specific therapies. Interventional studies to confirm these
hypotheses are essential and should be viewed as
mandatory before incorporation into routine clinical use.
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